NeuroSense Therapeutics : Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - Form 6-K

NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS


- PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa... | March 21, 2022

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom , ,Linkedin ,Twitter ,European Medicines Agency ,Prnewswire Neurosense Therapeutics Ltd ,Drug Administration ,Nasdaq ,Neurosense Therapeutics Ltd ,Neurosense Therapeutics Receives ,Sense Therapeutics ,Orphan Drug Designation ,Massachusetts General Hospital ,Neuron Derived Exosomes ,Neurosense Therapeutics Ltd Stock Exchange ,News ,Information ,Press Release ,Neurosense ,Herapeutics ,Eceives ,Fda ,Clearance ,F ,End ,Or ,Zrimec ,The ,Treatment ,Novel ,Combination ,Remonstrated ,Efficacy ,Safety ,N ,Hase Nrsn Il0011809592 ,